A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
about
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A randomized, phase 2 evaluati ...... us non-small cell lung cancer.
@en
type
label
A randomized, phase 2 evaluati ...... us non-small cell lung cancer.
@en
prefLabel
A randomized, phase 2 evaluati ...... us non-small cell lung cancer.
@en
P2093
P1433
P1476
A randomized, phase 2 evaluati ...... us non-small cell lung cancer.
@en
P2093
Aimee Bence Lin
Christian Schumann
Jesus Corral Jaime
Karla Hurt
Klaus Dalhoff
Luis Paz-Ares
Martin Sebastian
Michael Thomas
Miriam Alonso
P304
P356
10.1016/J.LUNGCAN.2017.03.001
P577
2017-03-06T00:00:00Z